BH-30236 is under clinical development by BlossomHill Therapeutics and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase I drugs for Myelodysplastic Syndrome have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BH-30236’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BH-30236 overview
BH-30236 is under development for the treatment of relapsed and refractory acute myelogenous leukemia (R/R AML), higher-risk myelodysplastic syndrome (HR-MDS). It acts by targeting CLK (CDC-like kinase). It is administered through oral route in the form of tablet.
BlossomHill Therapeutics overview
BlossomHill Therapeutics is developing precision medicines for the treatment of cancer and autoimmune diseases. The company is headquartered in San Diego, California, the US.
For a complete picture of BH-30236’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.